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Introduction: Circulating tumor cells (CTCs) are commonly isolated from the blood by targeting the epithelial cell
adhesion molecule (EpCAM) through positive selection. However, EpCAM can be downregulated during metastatic
progression, or it can be initially not present. We designed the present prospective trial to characterize CTCs as well
as other circulating cell populations in blood samples from women with metastatic breast cancer without
EpCAM-dependent enrichment and/or isolation technology.
Methods: A total of 32 patients with metastatic breast cancer were enrolled, and blood samples were processed
using a previously described negative depletion immunomagnetic methodology. Samples from healthy volunteers
were run as controls (n = 5). Multistep sequential labeling was performed to label and fix cell-surface markers
followed by permeabilization for cytokeratins (CK) 8, 18 and 19. Multiparametric flow cytometry (FCM) analysis was
conducted using a BD LSR II flow cytometer or a BD FACSAria II or FACSAria III cell sorter. Immunocytochemical
staining on postenrichment specimens for DAPI, EpCAM, CD45, CK, epidermal growth factor receptor and vimentin
was performed. Expression of these markers was visualized using confocal microscopy (CM).
Results: CD45-negative/CK-positive (CD45− CK+) populations with EpCAM + and EpCAM − expression were
identified with both FCM and CM from the negatively enriched patient samples. In addition, EpCAM + and
EpCAM − populations that were CK + and coexpressing the pan-hematopoietic marker CD45 were also noted.
There were more CK + EpCAM − events/ml than CK + EpCAM + events/ml in both the CD45− and CD45+ fractions
(both statistically significant at P ≤ 0.0005). The number of CK + CD45− and CK + CD45+ events per milliliter in blood
samples (regardless of EpCAM status) was higher in patient samples than in normal control samples (P≤ 0.0005 and
P≤ 0.026, respectively). Further, a significant fraction of the CK + CD45+ events also expressed CD68, a marker
associated with tumor-associated macrophages. Higher levels of CD45-CK + EpCAM −were associated with worse
overall survival (P = 0.0292).
Conclusions: Metastatic breast cancer patients have atypical cells that are CK + EpCAM − circulating in their blood.
Because a substantial number of these patients do not have EpCAM + CTCs, additional studies are needed to
evaluate the role of EpCAM − circulating cells as a prognostic and predictive marker.* Correspondence: maryam.lustberg@osumc.edu; priyams784@gmail.com;
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A recently held multidisciplinary workshop titled “Lorentz
Workshop Circulating Tumor Cell (CTC) Isolation and
Diagnostics: Toward Routine Clinical Use” defined a CTC
as a cell in the blood originating from either a primary or
metastatic tumor and having properties that enable mi-
gration into the circulation [1]. It was also mentioned
that a small subset of these CTCs may establish meta-
static growth after seeding in a tissue niche, with some of
them having undergone an epithelial–mesenchymal tran-
sition (EMT), in order to acquire the necessary mobility
and invasiveness to promote metastasis [2]. Historically,
the assumption that the CTC originated from an epithelial
solid tumor facilitated isolation and identification tech-
nologies that would select for surface markers consistent
with epithelial cells, such as the epithelial cell adhesion
molecule (EpCAM) [3-6]. Beyond expressing EpCAM,
the accepted definition of CTC requires that cells have
the following (as determined by a trained operator): nuclei;
cytokeratins (CKs) CK8, CK18 and CK19; no expression
of the pan-hematopoietic marker CD45; and morphology
consistent with a tumor cell. Based on these criteria, an
elevated number of CTCs before treatment or after one
cycle of treatment is an adverse prognostic factor in meta-
static breast cancer [3-7]. Researchers in two phase III tri-
als (SWOG-S0500, Southwest Oncology Group/National
Cancer Institute, ClinicalTrials.gov ID NCT0032018 (USA);
CirCe01, Institut Curie, ClinicalTrials.gov ID NCT01349842
(France)) currently underway are evaluating the use of
EpCAM+CTCs as predictive markers of response to sys-
temic therapy in metastatic breast cancer [8].
A significant challenge in using CTCs as a predictive
marker is that more than one-third of patients with meta-
static disease do not have detectable CTCs by EpCAM-
based technology [9]. Patients with undetectable CTCs
have a more favorable prognosis than patients with detect-
able CTCs. However, there may be individual patients
with poor prognoses who have CTCs not captured by
EpCAM-based positive enrichment, such as patients who
have undergone EMT with downregulation of EpCAM
and other epithelial markers. CTCs with an EMT-like
phenotype have been reported recently by several groups
[10-14]. In order to avoid the potential bias associated
with positive selection methods, we have developed a
negative enrichment strategy that relies on red blood cell
(RBC) lysis followed by a combination of well-defined
viscous flow and optimized magnetic forces to remove
CD45-expressing leukocytes from patients’ whole-blood
samples [15-17]. Using this enrichment system, we have
identified CTCs in all breast cancer stages [12]. In studies
conducted in patients with squamous cell carcinoma of
the head and neck, we have shown significantly reduced
disease-free survival with the presence of increased “puta-
tive” CTCs [11]. The term putative is used becauseEpCAM selection was not employed and, for those cells
tested, EpCAM was not present. Furthermore, many
CTCs expressed vimentin as well as epidermal growth fac-
tor receptor (EGFR), which is consistent with cells with a
mesenchymal phenotype [10,18].
We hypothesized that (1) we could detect more
CTCs and other atypical circulating cells if we used a
non-EpCAM-based negative enrichment approach and
(2) using flow cytometry (FCM) and confocal immuno-
cytochemistry (ICC) after negative depletion would allow
these putative CTCs to be phenotyped, further assisting
in the classification. To test this hypothesis, periph-
eral blood samples from patients with metastatic breast
cancer were obtained, subjected to the negative depletion
process and examined by multiparametric FCM and ICC
analysis to characterize the different subpopulations of
EpCAM+ and EpCAM − cells.
Methods
Cell cultures
The breast cancer cell lines MCF-7 (HTB-22) and MDA-
MB-231 (HTB-26) were procured from the American
Type Culture Collection (ATCC; Manassas, VA, USA) and
grown to mid-log phase in ATCC-specified culture media
at 37°C in a 5% CO2 atmosphere when specified. Cells
were harvested by washing the adherent cells with
phosphate-buffered saline and then incubating them with
Accutase (AT104; Innovative Cell Technologies, San
Diego, CA, USA) for 5 minutes at 37°C to remove the at-
tached cells from the culture flask. Accutase was then
neutralized with the culture media before the cells were
pelleted at 350 × g for 5 minutes. Cells were resuspended
in appropriate medium, depending on the downstream
application.
Patient samples and blood collection
Thirty-two metastatic breast cancer patients, who were
older than 18 years of age and had two or less prior lines
of systemic therapy were enrolled in The Ohio State
University Cancer Institutional Review Board (IRB)–
approved protocol. All patients gave their informed
consent to participate in the study. Blood samples were
collected after several standard blood tubes were drawn
for routine chemotherapy laboratory prior to initiation of
a new line of systemic therapy. Peripheral blood (7.8 to
17.7 ml) was collected in BD Vacutainer tubes (366643;
BD Biosciences, San Jose, CA, USA) for CTC enumeration
and processed within 4 hours of blood collection.
Normal control blood collection
Blood was collected from healthy volunteer donors (n = 5)
after obtaining their informed consent using an IRB-
approved protocol at The Ohio State University (OSU)
Medical Center and processed in the same manner as the
Lustberg et al. Breast Cancer Research 2014, 16:R23 Page 3 of 15
http://breast-cancer-research.com/content/16/2/R23patient samples. In addition, 11 to 18 ml of peripheral
blood was collected from ten individuals without a known
diagnosis of breast cancer before they underwent diagnos-
tic procedures at the Walter Reed Army Medical Center
Comprehensive Breast Care Center. Their blood samples
were utilized for ICC as confocal control specimens but
not were used for FCM. The protocol was approved
by the Cancer Institutional Review Board of the Walter
Reed Army Medical Center (IRBnet 354344), initiated
in January 2011, and informed, written consent was
obtained from all healthy volunteer donors. Peripheral ven-
ous blood was collected in BD Vacutainer tubes (362753;
BD Biosciences) and shipped overnight to OSU for
immediate processing. All samples were processed within
30 hours of blood draw.
Sample processing for negative depletion enrichment
Blood samples were kept at ambient temperature and
processed using a negative depletion immunomagnetic
methodology described previously [15,16,18]. Briefly, blood
samples were subjected to a RBC lysis step and labeled
with anti-CD45 tetrameric antibody complex (STEMCELL
Technologies, Vancouver, BC, Canada). Magnetic nanopar-
ticles were added and incubated with the cell suspen-
sion, which was run through the quadrupole magnetic
sorter system (Figure 1). A measure of the effectiveness
of the enrichment of the samples is represented as the
log10 of the ratio of the total number of nucleated cells be-
fore processing to the total number of nucleated cells after
processing [15,19].Figure 1 Enrichment and analysis methodology used in
this study.Multiparameter flow cytometry
Sample aliquots were taken prior to and after magnetic
labeling for setting up gating controls for multipara-
metric FCM. The enriched sample after separation was
split into two fractions. One fraction was stained using a
multistep sequential labeling protocol for FCM. Briefly,
the FCM sample was labeled for surface markers, fixed
with 4% paraformaldehyde to stabilize the surface stain-
ing, permeabilized with 0.1% Triton X-100 and stained
for intracellular proteins. The antibody fluorescent probe
combination used can be found in Additional file 1:
Table S1. A BD LSR II flow cytometer or a BD FACSAria
II cell sorter (BD Biosciences) equipped with three exci-
tation lasers (405 nm, 488 nm and 633 nm) was used for
initial FCM analysis. Both automatic and manual com-
pensation were evaluated for each patient sample.
During the study period, a BD FACSAria III cell sorter
was acquired. The FACSAria III is equipped with 355-,
488-, 561- and 635-nm lasers, which allows for fluores-
cein isothiocyanate and phycoerythrin dyes to be excited
with different lasers (488 nm and 561 nm) incident to
the cell at different locations in the stream, thereby sig-
nificantly reducing the need for compensation.
To determine whether the exclusion of nonviable cells,
determined with the LIVE/DEAD Fixable Aqua Dead
Cell Stain Kit (L34957; Life Technologies, Carlsbad, CA,
USA), would change the staining distribution of cells, se-
lected patient samples for this assay were assessed using
the FACSAria III system. All gates were determined on
the basis of unstained and single-color controls of each
patient sample, control samples from healthy volunteers
or buffy coats. Because at most two colors were excited
by a single laser (one dye per laser on the FACSAria III),
this gating strategy was equivalent to the fluorescence
minus one approach. For the samples using the viability
assay, the initial step included using a side scatter width
setting to exclude obvious doublets.
Confocal immunocytochemistry analysis of negatively
enriched patient samples
After negative depletion, an aliquot of cell suspension
preserved in 10% neutral buffered formalin was retained
for ICC staining and confocal microscopy (CM) ana-
lysis. The antibody-fluorescent probe combination used
can be found in the Additional file 2: Supplemental
Information. To facilitate high-quality image acquisition,
an Olympus FluoView FV1000 laser scanning confocal
microscope (Olympus Imaging America, Center Valley,
PA, USA) equipped with 405-nm, 488-nm, 543-nm and
633-nm lasers was used. All images were acquired, and
processed, using the Olympus FluoView Ver3.0 software
(Olympus America), which records all relevant instrument
settings and automatically determines pixel size (size
scales in the x, y and z directions). Additional file 2:
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the excitation filters or laser used, the emission filters used
and the excitation and emission spectra of the dyes.
Statistical analysis
Negatively enriched specimens were further classified into
subpopulations according to the expression levels of CD45,
CK and EpCAM, as visualized by FCM. CK + events per
milliliter of blood sample volume in each subpopulation
were summarized. One sample sign test was used to com-
pare the differences between any two subpopulations
from patient samples. A Wilcoxon rank-sum test (Mann–
Whitney U tests) was used to test the differences between
patient and healthy volunteer control groups. Sensitivity
analyses were conducted to confirm the conclusions using
a paired t-test (two-sample t-test with unequal variance
after proper data transformation). The P-values without
multiple comparison adjustment are reported.
Kaplan–Meier plots
Kaplan–Meier (KM analysis) was performed on several
of the subpopulations identified by multiparametric
FCM. Given the distinct grouping of cohorts required
for the KM estimator, we chose to use binary grouping:
patients with number of events per milliliter of blood
sample of the specific combination of markers below a
cutoff and above the cutoff. This cutoff was initially set
at one standard deviation above the mean of normal
blood controls, which works well when the specific cell
population is not rare. However, as is generally recog-
nized, the detection and analysis of rare events (approxi-
mately 0.1% and less), such as CTCs in peripheral blood
specimens by FCM, is challenging.
Authors of several experimental and theoretical re-
ports have attempted to provide a statistically based ap-
proach to reliably enumerate rare events by FCM. One
such approach is the use of Poisson distribution statis-
tics, which deal with the probability distribution of rare
events. A Poisson coefficient of variation (CV) associ-
ated with rare event data obtained in a flow cytometer




where, r is the number of events detected [20-23].
Equation (1) indicates that a CV of 10% requires 100
events to be positively detected and that a CV of 5%
requires 400 events.
The smallest blood sample we obtained in this study
was approximately 4 ml. To achieve a CV of 5%, 400
positive events needed to be detected. Therefore, in this
study, to be able to associate a CV of 5% to a measure-
ment, at least 100 events/ml of blood sample volumewere needed. Consequently, when the mean plus one
standard deviation of the normal controls was less than
100 events/ml of blood sample volume, we set 100
events/ml of blood sample volume as a cutoff. When the
mean plus standard deviation of the normal controls
was greater than 100, we set this value as the cutoff.
Results
Clinical characteristics
Thirty-two patients with metastatic breast cancer were
enrolled, including fifteen triple-negative (TNBC) estro-
gen receptor, progesterone receptor and Her2 (ER − PR −
Her2−), fourteen ER +Her2− and three Her2+ patients.
The median age of the patients was 55 years (range, 35 to
75 years). All patients had visceral involvement in one or
more sites. The patients’ clinical characteristics are sum-
marized in Table 1.
Immunomagnetic negative depletion of patient samples
Nucleated cell counts were determined prior to the RBC
lysis step, after RBC lysis and after magnetic depletion of
CD45 + -labeled cells. The average recovery of nucleated
cells after RBC lysis was 58%, the average nucleated log10
depletion was 2.7 and the total log10 depletion was 5.6
(range, 4.0 to 6.2). (A log10 depletion of 6.0 corresponds to
only one of one million cells left after processing).
Flow cytometry analysis of negatively enriched blood
Blood samples were analyzed by FCM after enrichment.
Data from spiking studies of cell lines as well as isotype
control studies are shown in Additional file 2: Supple-
mental Data. Figure 2a illustrates the CD45 gating strategy
for negative enriched control (healthy volunteer), and
Figure 2b shows the analysis of a representative sample
from a patient with metastatic breast cancer. Four dif-
ferent CK + subpopulations were identified by FCM
using the antibody conjugates targeting CD45, CK and
EpCAM. Selected samples obtained using the FAC-
SAria III were also stained with the LIVE/DEAD Fix-
able Aqua Dead Cell Stain Kit (n = 5). No significant
difference in the ratio of the four different subfractions
was observed when dead cells were excluded compared
to when they were not excluded (data not shown).
As shown in Figure 2b, and consistent with all of the
CD45 + CK + cells observed in all of the FCM analyses,
the vast majority of the cells weakly expressed CD45
(within an order of magnitude of signal intensity used to
“gate” between positive and negative cells) and appeared
in the side scatter and forward scatter plots in the region
consistent with more granulocyte-type cells. This obser-
vation is in contrast to more typically “bright” CD45
cells, which demonstrate less granulocytic characteristics
and are presumably more lymphocyte-like and are re-
moved in the magnetic depletion step.
Table 1 Clinical characteristics of the patientsa
Characteristics All patients (N = 32)
Age, years
Median 55
Range 35 to 75
Race
White 30 (94)
African American 2 (6)
















Type of breast cancer
ER − PR − Her2− (TNBC) 15 (47)
ER + Her2 − (ER+) 14 (44)
Her2+ 3 (9)
aECOG, Eastern Cooperative Oncology Group; ER, Estrogen receptor; PR,
Progesterone receptor; TNBC, Triple-negative breast cancer.
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flow cytometry analysis
To begin to further characterize this CD45 + CK + sub-
population, we added an anti-CD68 antibody added to
the staining protocol for 11 patient samples. For the
samples tested, more than 90% of the CD45 + CK +
events were CD68-positive. One representative sample is
presented in the bottom row of Figure 2b. Each dot plot
in the bottom row corresponds to the specific quadrants
in the middle row highlighted in red. The CD45 + CK +
EPCAM − population (middle row, center dot plot and
red-highlighted quadrant) is clearly positive for CD68.
The location of CD68+ cells on the side scatter axis is
consistent with the location of larger granular cells,
such as monocyte- and/or macrophage-like cells. Al-
though there are other weakly positive CD68 populations
in the two other dot plots in the third row, the stron-
gest CD68 positivity is present only in the CD45 + CK +
EpCAM − population.Distinct subpopulations of atypical cells are present in
metastatic breast cancer
Plots of the different subpopulations of the enriched
patient samples in terms of the number of events per
milliliter of blood sample volume, as identified by FCM,
are presented in Figure 3 (number of CD45− and CD45+
events per milliliter of blood sample volume). For com-
parison, the same subpopulations are also presented
for the healthy donors. As shown in Table 2, the CD45 +
CK + EpCAM−, CD45 + CK + EpCAM+, CD45 −CK+
EpCAM − and CD45 −CK + EpCAM+ events per milli-
liter of blood sample volume in patient samples were all
significantly higher than those in healthy control samples
(P = 0.03, P = 0.0007, P = 0.0004 and P = 0.0008, respect-
ively). The numbers of CK +CD45− and CK +CD45+
events per milliliter of blood sample volume, regardless of
EpCAM status, were also significantly higher in patient
samples than in control samples (P ≤ 0.0005 and P ≤ 0.026,
respectively). Consistent with the generally accepted con-
cept that the concentration of the traditionally defined
CTCs is not high enough to be routinely detected in FCM
analysis without sampling large blood volumes (that is,
greater than 20 ml), the CD45 −CK+ EpCAM+ popula-
tion concentrations were significantly greater than the
control; however, most of the concentrations were below
the 100 events per milliliter of blood sample volume
threshold, which corresponded to a CV of 5% (black solid
lines in Figure 3). The only subpopulation where the mean
plus one standard deviation of events in the controls was
greater than 100 events per milliliter of blood sample vol-
ume was CD45 + CK + EpCAM−. Consequently, for this
subpopulation, the threshold was set as the mean plus one
standard deviation of the controls for that subpopulation
(1,000 events per milliliter of blood sample volume).
Additional comparisons of the subpopulations present
in patient samples highlights that there were significantly
more CK + EpCAM − events than CK + EpCAM+ events
in both CD45− and CD45+ fractions (both P < 0.0005).
There were no significant differences among the breast
cancer subtypes (Figure 3).
Clinical outcome correlations
Combining all three types of metastatic breast cancer,
we asked whether elevated concentrations of these various
subtypes would be predictive of progression-free survival
or overall survival (OS) as determined by KM estimator
analysis. As a binary cutoff for the KM analysis, we used
the criteria for elevation that the concentration of events
per milliliter of blood sample volume should have a CV
of at least 5% and 100 or more events per milliliter
of blood sample volume for the CD45 −CK+ EpCAM −
population. For the CD45 + CK + EpCAM − population,
we used the mean plus one standard deviation of the
normal patient population as a cutoff. These four KM
Figure 2 (See legend on next page.)
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Figure 2 Comparative flow cytometry analyses. (a) CD45-depleted, buffy coat blood sample. (b) Representative triple-negative breast cancer
patient blood sample. All samples were labeled with antibodies against CD45; cytokeratins (CKs) CK8, CK18 and CK19; and epithelial cell adhesion
molecule (EpCAM). (a) and (b) are progression of plots. Top row, left to right: forward scatter area (FSC-A) and side scatter area (SSC-A); histograms
of unlabeled (red), CD45-stained (blue) and population expression after magnetic depletion (black); and dot plot of SSC versus CD45 expression
gated into CD45− expression, low CD45 expression and high CD45 high expression. Bottom row, left to right dot plots of EpCAM expression
versus CK expression for the CD45−, CD45 low and CD45 high populations. In part (b), a third row of plots is presented in which the events in
the red outlined quadrant in the second row are further investigated with respect to SS verses CD68 expression. APC, Allophycocyanin; Cy7,
Cyanine 7; FITC, Fluorescein isothiocyanate; FMO, Fluorescence minus one; PE, Phycoerythrin; PerCP, Peridinin chlorophyll protein.
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more per milliliter of blood sample volume were associ-
ated with significantly poorer OS (P = 0.029).
Confirmation of flow cytometry–defined subpopulations
using immunocytochemistry confocal microscopy
To provide independent visual confirmation of the
CD45− and CD45+ subtypes characterized by FCM ana-
lysis, four-color epifluorescence and confocal analysis of
cytospins from among several of the enriched metastatic
samples was conducted. Figures 5a and 5b show various
combinations of the antibody fluoroprobes used in this
study, confirming the specificity of Alexa Fluor custom-
conjugated antibodies (Molecular Probes, Sunnyvale,
CA, USA) to two breast cancer cell lines (MCF-7 andFigure 3 Scatterplots of the estimated number of cytokeratin-positive
flow cytometry. The solid black lines correspond to a Poisson distribution
have more than 100 CD45 + CK + EpCAM − events per milliliter of blood sa
molecule; ER, Estrogen receptor; TNBC, Triple-negative breast cancer.MDA-MB-231) and normal donor peripheral blood
mononuclear cells. Note that MCF-7 is positive for all
except CD45 and vimentin and MDA-MB-231 is negative
for CK8, CK18 and CK19 but positive for at least one of
CK1, CK4, CK5, CK6, CK10 or CK13 using a pan-CK
antibody (Sigma-Aldrich, St Louis, MO, USA). Additional
file 2: Supplemental Information provides further exam-
ples of controls, both using epifluorescence and CM.
Figure 6a presents low-magnification and high-
magnification confocal images of a representative pa-
tient (whose FCM data are presented in Figure 2b)
confirming the presence of various positive and negative
combinations of CK and EpCAM staining on both CD45−
and CD45+ subpopulations visualized by FCM. Colored
arrows are used in Figure 6 to facilitate identificationevents per milliliter of blood sample volume as determined by
coefficient of variation of 5%. Note that two normal donor specimens
mple volume. CK, Cytokeratin; EpCAM, Epithelial cell adhesion
Table 2 Atypical circulating subpopulationsa
Subpopulations CD45-CK + EpCAM+ CD45-CK + EpCAM− CD45 + CK + EpCAM+ CD45 + CK + EpCAM−
Patient samples (n = 32) 33 (10.5 to 112.5) 275 (110 to 877.5) 89.5 (36 to 224.5) 1,623 (163.5 to 3,725)
Control (n = 5) 0 (0 to 0.4) 4.6 (2.3 to 6.7) 5 (0.5 to 7.1) 48.9 (7.4 to 402.1)
P-values 0.0008 0.0004 0.0007 0.03
aCK, Cytokeratin; EpCAM, Epithelial cell adhesion molecule. The values in each cell are medians (25% to 75% quartile range). P-values were calculated using the
Mann–Whitney U tests of the subpopulations between control and patient samples.
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be noted that it is very rare to find a DAPI + CD45 + CK-
EpCAM − cell in these enriched samples, given the average
log10 value of 2.7 for depletion of nucleated cells.
Additional file 2: Supplemental Information provides
low-magnification epifluorescent images of a patient
sample prior to and after magnetic depletion.
Figure 6b presents high-magnification representative
confocal images of expression of a traditional CTC (row 1),
a putative CTC that is EpCAM − (row 2), a cell with absent
CKs (CK8, CK18 and CK19) but EpCAM+ (row 3), an
atypical cell that is EpCAM+ but absent CKs (CK8, CK18
and CK19) and series of CD45 + CK + cells that were re-
corded in almost all of the FCM analyses (rows 4 and 5).
Multiparametric immunocytochemistry with vimentin and
epidermal growth factor receptor staining
The FCM analysis and the confocal images indicate that
other rare cells that do not fit the traditional definitionFigure 4 Kaplan–Meier plots of progression-free survival and overall
with 17 estrogen receptor–positive or Her2-positive patients. (a) P
(b) Plots for CD45 + CK + EpCAM+/EpCAM − subpopulations are shown. CKof CTCs were present (that is, CD45 −CK + EpCAM−).
To further phenotypically characterize these cells, differ-
ent staining protocols were used, including replacing
EpCAM and/or CD45 with vimentin or EGFR. Figure 7
presents a cytospin of enriched TNBC patient blood
stained with 4′,6-diamidino-2-phenylindole (DAPI), CD45,
CK and vimentin replacing EpCAM. Row 1 shows a trad-
itional CTC negative for vimentin. Rows 2 and 3 show
CD45− cells that have both epithelial (CK) and mesenchy-
mal (vimentin) marker expression. Figure 8 presents
further analysis in which EGFR replaces the CD45 stain-
ing. The four rows represent the four different staining
combinations observed in the same cytospin of the blood
sample from the same patient, again demonstrating sub-
population heterogeneity in metastatic patients. It should
also be noted that CD45 was used in the examples pre-
sented in Figure 7 and that all of the vimentin-positive
cells are CD45− and therefore not traditionally defined
hematopoietic cells. In Figure 8, though CD45 was notsurvival of 15 triple-negative breast cancer patients combined
lots for CD45-CK + EpCAM+/EpCAM − subpopulations are shown.
, Cytokeratin; EpCAM, Epithelial cell adhesion molecule.

















Figure 5 Staining controls for different phenotypic markers used. (a) The top three rows are confocal immunofluorescent images of normal
donor peripheral blood mononuclear cells (PBMCs), MCF-7 and a mixture of normal donor PBMCs and MCF-7 stained with cytokeratin (CK)
antibody (green), CD45 antibody (red), epithelial cell adhesion molecule (EpCAM) (white) and 4′,6-diamidino-2-phenylindole (DAPI; blue). The
bottom two rows of images show healthy donor PBMCs and MDA-MB-231 stained with the same antibody dye conjugates and the CK antibody
replaced by pan-CK versions. (b) Confocal immunofluorescent images show healthy donor PBMCs, MCF-7 and MDA-MB-231 stained with DAPI
(blue); anti-CK7, anti-CK8, anti-CK18 and anti-CK19 antibody (green); antivimentin (red); and anti–epidermal growth factor receptor (EGFR; white).
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Figure 6 Examples of different cell types found in the peripheral blood of triple-negative breast cancer patients. (a) Peripheral blood
mononuclear cells (PBMCs) of representative triple-negative breast cancer patients shown in low- and high-magnification confocal microscopy
immunofluorescent images stained with cytokeratin (CK) antibody (green), CD45 antibody (red), epithelial cell adhesion molecule (EpCAM) (white)
and 4′,6-diamidino-2-phenylindole (DAPI; blue). To assist in the identification of different cell types, based on staining pattern, we added arrows
of different color according to the key provided. (b) High-magnification confocal images from a patient peripheral blood sample highlighting the
different staining combinations observed.
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EGFR or cytokeratins, further decreasing the probability
that these cells are of hematopoietic origin as sometimes
suggested.
Discussion
The currently accepted definition of a CTC is a nucleated
cell that is positive for epithelial marker expression of
EpCAM and cytokeratins CK8, CK18 and CK19 and nega-
tive for the pan-hematopoietic marker CD45. In addition
to identifying these traditional CTCs, we show herein that
there are other abnormal circulating cell populationspresent in blood samples from metastatic breast cancer
patients. These populations include EpCAM − cells that
are CK+, cells that express mesenchymal markers but few
or no epithelial markers and cells which express both
hematopoietic and epithelial makers. These findings high-
light the fact that blood from metastatic breast cancer pa-
tients has a heterogeneous mixture of abnormal cells and
is consistent with other reports of heterogeneous mixtures
of putative CTCs [4,13,14,24].
Multiple studies have shown that CTCs detected by
EpCAM+ selection are prognostic in metastatic breast




DAPI CK CD45 Vimentin
Figure 7 Confocal immunofluorescent images of four representative triple-negative breast cancer patients. Images are stained with
cytokeratin (CK) antibody (green), CD45 antibody (red), vimentin (white) and 4′,6-diamidino-2-phenylindole (DAPI; blue). Note that the
vimentin-positive cells are negative for the hematopoietic marker CD45. DIC, Differential interference contrast images; EGFR, Epidermal
growth factor receptor.
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ive markers in treatment decision-making [8]. However,
on average, only up to 65% of patients with metastatic
breast cancer have identifiable CTCs that fit these criteria
[3,9]. There is wide speculation regarding why patients
with metastatic breast cancer may have undetectable
CTCs. As a group, patients with undetectable CTCs may
have a better prognosis, but the lack of circulating bio-
markers still can make evaluation of targeted therapies
challenging. Additionally, it is possible that some tumors
with aggressive features may have undergone EMT, which
would downregulate epithelial markers such as EpCAM.
Further, the molecularly classified basal-like breast tumors
have a low or nonexistent expression of EpCAM and have
increased expression of mesenchymal markers [30]. Stud-
ies utilizing cell lines have established the limitation of
EpCAM+ selection in recovering basal-like tumor cell
lines [31], although no definitive study has clearly illus-
trated that this type of enrichment is not successful in
basaloid tumors. Moreover, several studies have shown
the EpCAM+ selection is still a reliable prognostic marker
in patients with metastatic TNBC [32-35].
However, the question remains whether there are add-
itional cell populations of interest that could be missedusing EpCAM preselection in patients with metastatic
breast cancer. Konigsberg et al. compared two CTC iso-
lation methods: an immunomagnetic positive selection
approach targeting EpCAM (MACS CD326 (human epi-
thelial antigen) MicroBeads; Miltenyi Biotec, San Diego,
CA, USA) and an antibody-independent, density gradi-
ent centrifugation device which assumes CTCs have dis-
tinct, different densities compared to normal blood
components (OncoQuick Plus; Greiner Bio-One, Frick-
enhausen, Germany) [36]. Their spiking studies con-
firmed the limitations of relying on a positive selection
targeting EpCAM to identify all atypical cell populations
within a given sample across a heterogeneous disease,
consistent with other cell line studies [31]. However, it
should be noted that their study included only CK
markers and did not further characterize these cells. In
addition, studies demonstrating the clinical utility of
OncoQuick Plus isolated CTCs are limited. The clinical
significance of EpCAM −CTC is not clear. Most re-
cently, EpCAM − CTCs isolated by FCM and having a
Notch1+/EGFR+/Her2+/EpCAM − phenotype resulted
in established cells lines and also demonstrated a high-








Figure 8 Further combination of confocal images. Images were produced by cytospin of a triple-negative breast cancer blood sample stained
with 4′,6-diamidino-2-phenylindole (DAPI); antibodies against cytokeratins CK7, CK8, CK18 and CK19; anti-vimentin; and anti–epidermal growth
factor receptor (EGFR). The four rows represent the four different combinations observed in the blood sample from this patient.
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press EpCAM but still be CD45− significantly increases
the number of potential cells that can be called CTCs.
This phenomenon is clearly seen in the dot plot of the
CD45− EpCAM versus CK data for one of the patients
(Figure 2b, second row, first plot). In that plot, though
there are a few events in the EpCAM+CK+ quadrant a
much larger number of cells are present in the EpCAM −
CK+ quadrant. These EpCAM −CK+ cell concentrations
are higher in the patient samples than in those of the
healthy donors (Table 2) and are associated with worse
OS based on our preliminary results (Figure 4). Most
striking is that in this feasibility study, with a limited num-
ber of patients, elevated levels of EpCAM −CK+CD45−
cells correlated with poor OS, not just in TNBC patients
but also in ER + patients. A larger pool of candidate atyp-
ical circulating cells would expand the possibility of fur-
ther molecular profiling and analysis of targeted therapies.
Currently, narrowly defined, traditional CTC populations
can be very low in a large number of patients with meta-
static breast cancer.
The confocal images presented herein confirm the het-
erogeneity of the populations observed in the FCM ana-
lysis with respect to CK, CD45 and EpCAM expression,
including the classically defined CTC (CD45 −CK+EpCAM+), as well as of other atypical populations, includ-
ing CD45 −CK + EpCAM − and CD45 −CK − EpCAM+.
The size of many of these cells is similar to the size of typ-
ical white blood cells. Although it would be highly de-
sirable to obtain estimates of the number of these different
subtypes per milliliter of patient blood sample volume,
such counting using a confocal microscope is not practical.
It is possible to obtain cell counts using a fluorescence
microscope, this technology does not have the ability to re-
liably distinguish between positive and negative signals at
the higher wavelengths. The CM analysis also demon-
strates the presence of cells that express vimentin and
EGFR, possibly suggesting that these cells have undergone
EMTassociated with the basal subtype.
Our study findings raise several questions. Do EpCAM −
CK+ cells correspond to a subpopulation of CTCs with
more aggressive features? These EpCAM cells with low
expression are of interest because they can express mesen-
chymal markers such as EGFR and vimentin, biomarkers
that are associated with EMT. As shown in Figures 7 and
8, CK + cells that were positive for vimentin and or EGFR
were identified by ICC and FCM, and we found similar
rare cells with mesenchymal markers in the blood of pa-
tients with head and neck malignancies [10]. In addition,
other unusual cells were identified, including those that
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CK18 and CK19 but positive for vimentin, which is sug-
gestive of the presence of an EMT phenotype. Vimentin
can be present in normal blood cells. However, in all of
our previous studies and the present study, we have not
observed any cells that stained positive with both CD45
and vimentin, as shown in Figure 5b. Further, we have not
observed any vimentin-positive cells in the blood of our
healthy volunteer controls. When we visualized vimentin-
positive patient samples, as shown in Figures 7 and 8, we
found that the cells were either CD45− negative or posi-
tive for several other markers not associated with normal
blood (CK and EGFR). These rare cell populations would
not have been identified by utilizing a positive selection
methodology initially targeting EpCAM.
In addition to EpCAM+ and EpCAM − cell popula-
tions, herein we show that there are other abnormal cir-
culating cell types, including the perplexing population
of cells that expresses both CD45 and CK. This population
has been noted by others but has not been described in
detail and is believed to be primarily an artefact [1,24].
Given the limitations of the enrichment strategy, isolation
technology, ICC using fluorescent dyes and the belief that
the cells are artefacts, these cells have rarely been isolated
and characterized.
The significant number of CD45 +CK + cells in all pa-
tient samples raises the question whether these are analysis
artefacts, such as cell doublets or cells having nonspecific
binding of the anti-CK antibody or the anti-CD45 anti-
body. In patient samples in which we used the viability dye
and side scatter width settings, which is reported to
exclude dead cells and obvious doublets during FCM
analysis, we still observed CD45 + CK + cells. In fact, the
addition of these FCM selection criteria did not signifi-
cantly lower the number of CD45 + CK + events.
These data, along with multiparametric confocal im-
ages, suggest that there is a population of atypical cells
that have both hematopoietic and epithelial-like charac-
teristics that merit further investigation. Although the
staining of CD68 began late in our present study, we ob-
served these CD68 subpopulations in multiple independ-
ent patient samples. Further, this specific combination of
staining is not observed in normal patient samples.
Although we acknowledge that nonspecific binding is
a possible explanation for this population, the positive
CD68 expression is consistently present in higher levels
in metastatic patients and there is a trend toward in-
creased levels at the time of progression. Recent re-
ports have highlighted that increased tumor-associated
macrophages in primary breast tumors are associated with
worse outcomes and chemotherapy resistance [38]. How-
ever, concurrent changes in the blood have not been re-
ported yet. Additional studies aimed at multiparametric
characterization of this population, including CD16, CD14and colony-stimulating factor receptor type 1 staining, are
underway.
This study has several limitations, including a limited
sample size and lack of a test and validation set to con-
firm correlations with clinical outcomes. However, this
pilot study highlights the importance of the unbiased
characterization of the atypical circulating cells that are
present in metastatic breast cancer patients and that the
traditional CTCs make up a minority of the abnormal cir-
culating cells in blood samples from patients with meta-
static breast cancer.
Conclusions
To the best of our knowledge, this report is the first to de-
scribe the presence of circulating, nucleated EpCAM+
CK+ and EpCAM −CK+ in the blood samples of a series
comprising only metastatic breast cancer patients, as
demonstrated by multiparametric FCM concurrently with
ICC. Characterization of these subpopulations through
advancements in multiparametric spectral analysis and
molecular marker analysis may further elucidate the na-
ture of these cells. Additional studies are needed to dis-
cern which of these subpopulations are most clinically
relevant, although our preliminary results suggest that the
CK + EpCAM − population is of interest.Additional files
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